ImmunityBio

ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration

Retrieved on: 
Thursday, January 19, 2023
Oncology, FDA, Health, Clinical Trials, General Health, Biotechnology, Dor, Survival rate, DCR, Chan, OS, ASCO, Agency, PFS, NMIBC, RECIST, Medicine, Cohort study, Safety, Pancreatic cancer, Hoag (health network), Maintenance, NK, BLA, College, Patient, Radiation, Mortality, ORR, Society, BCG, Progression-free survival, PDUFA, Pharmaceutical industry, ImmunityBio

The results were presented at the American Society of Clinical Oncology Gastrointestinal (ASCO GI) conference in San Francisco January 19-21.

Key Points: 
  • The results were presented at the American Society of Clinical Oncology Gastrointestinal (ASCO GI) conference in San Francisco January 19-21.
  • In subjects with CA 19-9 levels less than 4120 IU/ml (N=40), the median OS was 6.9 months (95% CI: 5.7,10.9).
  • The Agency advised the company to conduct randomized trials in metastatic BCG-unresponsive NMIBC papillary disease and in late-stage metastatic pancreatic cancer.
  • Today, surgery and subsequent adjuvant chemotherapy are the preferred treatment options for pancreatic cancer, but the five-year survival rate for late-stage cases is just 3%.

ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor

Retrieved on: 
Monday, December 12, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Shelf registration, Therapy, NantWorks, Severe acute respiratory syndrome coronavirus 2, HIV, Food, Attention, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Immunotherapy, CIS, Infection, BLA, Sale, GMP, Disease, Form S-3, FDA, Treatment of lung cancer, Form, Cancer, BCG, COVID-19, Prospectus, Vaccine, Clinical trial, Telephone, Patrick Soon-Shiong, Nicollet Mall, NMIBC, Physician, Pharmaceutical industry, Security (finance), ImmunityBio

If fully exercised the warrants could result in additional gross proceeds of up to $60 million.

Key Points: 
  • If fully exercised the warrants could result in additional gross proceeds of up to $60 million.
  • The warrants will become immediately exercisable at any time after they are issued and expire two years after the initial issuance date.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.
  • ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.

Ziosoft Introduces Next Generation Ziostation Platform at Annual Radiological Society of North America Conference

Retrieved on: 
Monday, November 28, 2022
Marketing, Software, AI, The San Diego Union-Tribune, Weeping Angel, ImmunityBio, RSNA, Workflow, 3D, MD, Rembrandt, Google Images, Automation, Revora, Abraxis BioScience, Video game console, Video game, NantWorks

CHICAGO, Nov. 28, 2022 /PRNewswire-PRWeb/ -- Ziosoft, a pioneer in 3D/4D AI medical visualization, is introducing its newest software for its flagship Ziostation system at the annual Radiologicaly Society of North America (RSNA) being held November 27-30, 2022 in Chicago. The Revoras platform (work in progress) offers numerous productivity enhancements and new visualization technology including the unique Ziosoft Rembrandt image rendering capability.

Key Points: 
  • The Revoras platform (work in progress) offers numerous productivity enhancements and new visualization technology including the unique Ziosoft Rembrandt image rendering capability.
  • It is enabled, along with other enhancements, through our new, advanced Revoras platform, which is being introduced at RSNA this year."
  • Advanced imaging technology immerses users in simulated environments for exploration, analysis, synthesis and presentation, all of which are enabled by the Revoras platform.
  • "Revoras is a comprehensive advanced imaging platform that is the newest generation Ziosoft technology," said Rajeev Taitriya, vice president of marketing and business development for Ziosoft.

LadRx Corporation Issues Corporate Update for 3Q22

Retrieved on: 
Thursday, November 17, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, FDA, ImmunityBio, Niemann–Pick disease, Toxicology, Maitansine, CRL, NPC, Immunity, Controlled internal drug release, Cancer, NDA, Annual report, Glioblastoma, Research, Nature, Doxorubicin, Pancreatic cancer, LADR, Therapy, Endpoint security, OTCQB, Patient, Vaccine, Pharmaceutical industry, Arimoclomol, IND, Aldoxorubicin

LadRx Corporation (OTCQB: LADX) (LadRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below update to stockholders.

Key Points: 
  • LadRx Corporation (OTCQB: LADX) (LadRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below update to stockholders.
  • Thank you for your continued support of LadRx, and we look forward to continuing to update you on our progress.
  • LadRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
  • LadRx Corporation (OTCQB: LADX) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer.

ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference

Retrieved on: 
Thursday, November 17, 2022
COVID-19, Infectious Diseases, Public Relations, Investor Relations, Clinical Trials, Communications, Biometrics, Biotechnology, General Health, Pharmaceutical, Health, Immunotherapy, FDA, BCG, GMP, HIV, Clinical trial, NMIBC, Infection, Severe acute respiratory syndrome coronavirus 2, Cancer, BLA, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, COVID-19, Treatment of lung cancer, CIS, Food, Vaccine, Pharmaceutical industry, ImmunityBio

ImmunityBio is a vertically-integrated, clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases.

Key Points: 
  • ImmunityBio is a vertically-integrated, clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases.
  • These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.
  • ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.

NEJM Evidence Publishes Results for ImmunityBio’s QUILT 3.032 Registrational Trial of IL-15 Superagonist N-803 Plus BCG in Patients with Bladder Cancer

Retrieved on: 
Thursday, November 10, 2022
FDA, Infectious Diseases, Health, Clinical Trials, Oncology, Review, Private Securities Litigation Reform Act, Cancer, Forward-looking statement, Pembrolizumab, NEJM, Vaccine, Treatment of lung cancer, BCG, Severe acute respiratory syndrome coronavirus 2, Pancreatic cancer, Cystectomy, Food, Immunotherapy, CR, Breakthrough therapy, Incidence, Population, CRS, BLA, COVID-19, DFS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SEC, Medicine, Fast Track, TURBT, Patient, U.S. Securities and Exchange Commission, Infection, CIS, Large-cell lung carcinoma, Probability, Disease, NAI, Clinical trial, Maintenance, NK, GMP, Immune system, Progression-free survival, Nominal interest rate, HIV, FDA, Trial of the century, Pharmaceutical industry, ImmunityBio, NMIBC, FDA, Infectious Diseases, Health, Clinical Trials, Oncology

NEJM Evidence has published results from the QUILT 3.032 trial studying N-803 plus BCG in adults with NMIBC CIS with or without Ta/T1 papillary disease.

Key Points: 
  • NEJM Evidence has published results from the QUILT 3.032 trial studying N-803 plus BCG in adults with NMIBC CIS with or without Ta/T1 papillary disease.
  • Patients with intermediate or high-risk NMIBC typically receive a treatment of transurethral resection of the bladder tumor (TURBT) followed by BCG intravesical instillation.
  • However, cancer will recur in 30% to 40% of patients with NMIBC despite adequate treatment with BCG.
  • Moreover, even among those in whom a complete response is achieved with BCG, up to 50% see their cancer return.

The Access to Advanced Health Institute Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature

Retrieved on: 
Wednesday, November 2, 2022
COVID-19, Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, RNA, MD, Face, SaRNA, COVID, Science, Partnership, Clinical trial, Cancer, Research, Infectious Disease Research Institute, Degenerative disease, COVID-19, Disease, Immune system, Immunodeficiency, Transport, Government, Fungus, NPJ, Technology, NLC, Vaccine, Temperature, Access, Severe acute respiratory syndrome coronavirus 2, Parasitism, Solution, ImmunityBio

Today, the Access to Advanced Health Institute (AAHI) announced results from a study of their new RNA vaccine against COVID-19.

Key Points: 
  • Today, the Access to Advanced Health Institute (AAHI) announced results from a study of their new RNA vaccine against COVID-19.
  • AAHIs RNA vaccines can easily be freeze-dried for long-term room temperature or refrigerated stability (10+ months).
  • The SARS-CoV-2 RNA vaccine candidate, AAHI-SC2, is currently being evaluated in liquid form in a first-in-human Phase 1 / 2 clinical trial sponsored by ImmunityBio in South Africa ( NCT05370040 ).
  • The improved temperature stability of AAHI-SC2 enables more equitable access to COVID RNA vaccines, especially in rural and remote communities where resources are limited.

ImmunityBio to Participate in the Jefferies London Healthcare Conference

Retrieved on: 
Thursday, October 27, 2022
Biotechnology, Pharmaceutical, AIDS, Oncology, Health, COVID-19, Infectious Diseases, Clinical Trials, Review, BCG, Infection, Private Securities Litigation Reform Act, BLA, Cancer, NMIBC, Forward-looking statement, Disease, COVID-19, Clinical trial, FDA, GMP, U.S. Securities and Exchange Commission, Treatment of lung cancer, Vaccine, CIS, Severe acute respiratory syndrome coronavirus 2, SEC, HIV, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Immunotherapy, Therapy, Pharmaceutical industry, ImmunityBio

ImmunityBio is a clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases.

Key Points: 
  • ImmunityBio is a clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases.
  • These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.
  • ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.

Ziosoft Highlights Virtual Surgical Visualization Solutions at Annual American College of Surgeons Conference

Retrieved on: 
Monday, October 17, 2022
SAN, Rapid prototyping, Lung, Time, American College of Surgeons, Hepatic artery proper, Efficiency, Anesthesia, Workflow, Portal vein, Bronchus, ACS, Abraxis BioScience, CT, Software, Solution, Marketing, MD, Health, Liver, Vein, Weeping Angel, The San Diego Union-Tribune, American College, ImmunityBio, Ownership, Surgeon, Medical imaging, NantWorks

SAN DIEGO, Oct. 17, 2022 /PRNewswire-PRWeb/ -- Ziosoft, a pioneer in 3D/4D AI medical visualization, will highlight its virtual surgical visualization solutions at the annual American College of Surgeons (ACS) conference being held October 16-20, 2022 in San Diego, California. The company will showcase software tools, such as lung and liver segmentation, to help enable efficient surgical planning analysis.

Key Points: 
  • SAN DIEGO, Oct. 17, 2022 /PRNewswire-PRWeb/ -- Ziosoft, a pioneer in 3D/4D AI medical visualization, will highlight its virtual surgical visualization solutions at the annual American College of Surgeons (ACS) conference being held October 16-20, 2022 in San Diego, California.
  • The company will showcase software tools, such as lung and liver segmentation, to help enable efficient surgical planning analysis.
  • "Ziosoft's segmentation analysis software provides extensive capabilities for surgical planning," said Rajeev Taitriya, vice president of marketing and business development for Ziosoft.
  • "These analytical tools assist surgeons to see and think in 3D, crossing the bridge between the gap of diagnostic readers to the operating table.

LadRx Corporation Announces OTCQB Ticker Change to LADX

Retrieved on: 
Wednesday, October 5, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Niemann–Pick disease, Therapy, SEC, CUSIP, ImmunityBio, Patient, Research, Annual report, NPC, Cancer, Gaucher's disease, CYTR, Doctor of Philosophy, Nature, Gaucher, OTCQB, Pharmaceutical industry, Aldoxorubicin

LadRx Corporation (OTCQB: LADX) (LadRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, October 6, 2022.

Key Points: 
  • LadRx Corporation (OTCQB: LADX) (LadRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, October 6, 2022.
  • Chief Executive Officer Stephen Snowdy, PhD commented, Following up on other changes we have made this year, including the change of our name to LadRx Corporation, we are updating our ticker symbol to better reflect our Companys focus and brand.
  • There is no action required by the Companys current shareholders and the change in its ticker symbol will have no effect on its corporate structure or business.
  • LadRx Corporation (OTCQB: LADX) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer.